venetoclax – Patient Worthy

source: pixabay.com

SEQUOIA Trial Results Show Remarkable Response Rate in High-Risk CLL Subgroup

Post author:Rose Duesterwald
Post published:February 4, 2022
Post category:Chronic Lymphocytic Leukemia small lymphocytic lymphoma

Targeted Oncology recently featured a discussion by Dr. Jennifer Brown, director of Dana Farber’s Chronic Lymphocytic Leukemia Center, on the interim results from the SEQUOIA Phase 3 trial. The trial…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More